Cancer Monoclonal Antibodies Market by Type and Geography - Forecast and Analysis 2021-2025

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem
  • Exhibit 01: Parent market
  • Exhibit 02: Market characteristics

• 2.2 Value chain analysis
  • Exhibit 03: Value Chain Analysis: Pharmaceuticals

3 Market Sizing

• 3.1 Market definition
  • Exhibit 04: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
  • Exhibit 05: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025
  • Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
  • Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
  • Exhibit 08: Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers
  • Exhibit 09: Bargaining power of buyers

• 4.3 Bargaining power of suppliers
  • Exhibit 10: Bargaining power of suppliers

• 4.4 Threat of new entrants
  • Exhibit 11: Threat of new entrants

• 4.5 Threat of substitutes
  • Exhibit 12: Threat of substitutes

• 4.6 Threat of rivalry
  • Exhibit 13: Threat of rivalry

• 4.7 Market condition
  • Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Type

• 5.1 Market segments
  • Exhibit 15: Type - Market share 2020-2025 (%)

• 5.2 Comparison by Type
  • Exhibit 16: Comparison by Type

• 5.3 Naked monoclonal antibodies - Market size and forecast 2020-2025
  • Exhibit 17: Naked monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
  • Exhibit 18: Some US-FDA and EU approved naked cancer monoclonal antibodies
  • Exhibit 19: Naked monoclonal antibodies - Year-over-year growth 2020-2025 (%)

• 5.4 Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025
  • Exhibit 20: Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
  • Exhibit 21: Conjugated and bi-specific monoclonal antibodies - Year-over-year growth 2020-2025 (%)

• 5.5 Market opportunity by Type
  • Exhibit 22: Market opportunity by Type

6 Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation
  • Exhibit 24: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison
  • Exhibit 25: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025
  • Exhibit 26: North America - Market size and forecast 2020-2025 ($ million)
  • Exhibit 27: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025
  • Exhibit 28: Europe - Market size and forecast 2020-2025 ($ million)
  • Exhibit 29: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025
  • Exhibit 30: Asia - Market size and forecast 2020-2025 ($ million)
  • Exhibit 31: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025
  • Exhibit 32: ROW - Market size and forecast 2020-2025 ($ million)
  • Exhibit 33: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries
  • Exhibit 34: Key leading countries

• 7.8 Market opportunity by geography
  • Exhibit 35: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges
  • Exhibit 36: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Vendor landscape
  • Exhibit 37: Vendor landscape

• 9.2 Landscape disruption
  • Exhibit 38: Landscape disruption
  • Exhibit 39: Industry risks

• 9.3 Competitive scenario

10 Vendor Analysis

• 10.1 Vendors covered
  • Exhibit 40: Vendors covered

• 10.2 Market positioning of vendors
  • Exhibit 41: Market positioning of vendors

• 10.3 Amgen Inc.
  • Exhibit 42: Amgen Inc. - Overview
  • Exhibit 43: Amgen Inc. - Business segments
  • Exhibit 44: Amgen Inc. – Key news
  • Exhibit 45: Amgen Inc. - Key offerings

• 10.4 Astellas Pharma Inc.
  • Exhibit 46: Astellas Pharma Inc. - Overview
  • Exhibit 47: Astellas Pharma Inc. - Product and service
  • Exhibit 48: Astellas Pharma Inc. - Key offerings

• 10.5 AstraZeneca Plc
  • Exhibit 49: AstraZeneca Plc - Overview
  • Exhibit 50: AstraZeneca Plc - Product and service
  • Exhibit 51: AstraZeneca Plc – Key news
  • Exhibit 52: AstraZeneca Plc - Key offerings

• 10.6 Bristol Myers Squibb Co.

• 10.7 F. Hoffmann La Roche Ltd.
  • Exhibit 58: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 59: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 60: F. Hoffmann La Roche Ltd. – Key news
  • Exhibit 61: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 62: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Johnson and Johnson Inc.
  • Exhibit 63: Johnson and Johnson Inc. - Overview
  • Exhibit 64: Johnson and Johnson Inc. - Business segments
  • Exhibit 65: Johnson and Johnson Inc. – Key news
  • Exhibit 66: Johnson and Johnson Inc. - Key offerings
  • Exhibit 67: Johnson and Johnson Inc. - Segment focus

• 10.9 Merck and Co. Inc.
  • Exhibit 68: Merck and Co. Inc. - Overview
  • Exhibit 69: Merck and Co. Inc. - Business segments
  • Exhibit 70: Merck and Co. Inc. – Key news
  • Exhibit 71: Merck and Co. Inc. - Key offerings
  • Exhibit 72: Merck and Co. Inc. - Segment focus

• 10.10 Novartis AG
  • Exhibit 73: Novartis AG - Overview
  • Exhibit 74: Novartis AG - Business segments
  • Exhibit 75: Novartis AG. – Key news
  • Exhibit 76: Novartis AG - Key offerings
  • Exhibit 77: Novartis AG - Segment focus

• 10.11 Pfizer Inc.
  • Exhibit 78: Pfizer Inc. - Overview
  • Exhibit 79: Pfizer Inc. - Business segments
  • Exhibit 80: Pfizer Inc.- Key news
  • Exhibit 81: Pfizer Inc. - Key offerings

• 10.12 Sanofi SA
  • Exhibit 82: Sanofi SA - Overview
  • Exhibit 83: Sanofi SA - Business segments
  • Exhibit 84: Sanofi SA – Key news
  • Exhibit 85: Sanofi SA - Key offerings
  • Exhibit 86: Sanofi SA - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$
  • Exhibit 87: Currency conversion rates for US$

• 11.3 Research methodology
  • Exhibit 88: Research Methodology
  • Exhibit 89: Validation techniques employed for market sizing
  • Exhibit 90: Information sources

• 11.4 List of abbreviations
  • Exhibit 91: List of abbreviations